Georgian medical news · 2026
EFFICACY ANALYSIS OF SHENFU INJECTION COMBINED WITH DAPAGLIFLOZIN IN THE TREATMENT OF SEPTIC HEART FAILURE.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Chuan-Min, Guo Jia-Shu
Аннотация
OBJECTIVE: To explore the clinical efficacy and safety of Shenfu Injection combined with Dapagliflozin in the treatment of septic heart failure (HF), and to provide a theoretical basis for clinical application.
METHODS: A total of 40 patients with septic HF admitted to the Intensive Care Unit (ICU) of Qingdao Jiaozhou Central Hospital from July 2019 to June 2022 were selected and randomly divided into the observation group and the control group, with 20 patients in each group. The control group was treated with Dapagliflozin tablets and basic anti-heart failure drugs, while the observation group was additionally given Shenfu Injection on the basis of the control group's treatment, with a course of 7 consecutive days. The changes of serum N-terminal B-type natriuretic peptide precursor (NT-proBNP), cardiac troponin I (cTnI), inflammatory indicators (CRP, PCT, interleukin-6), Acute Physiology and Chronic Health Evaluation Ⅱ (APACHE Ⅱ) score, and cardiac color Doppler ultrasound indicators [left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), left ventricular end-diastolic volume (LVEDV), stroke volume (SV)] were compared between the two groups before and after treatment. The clinical efficacy and safety of the two groups were evaluated. Sample size calculation was based on the primary outcome indicator of LVEF improvement. Referring to previous similar studies, the expected mean difference in LVEF improvement between the two groups was 5%, with a standard deviation of 6%. Using a two-sided test with α=0.05 and power=80%, the calculated minimum sample size per group was 18. Considering a potential dropout rate of 10%, 20 patients were included in each group to ensure the statistical power of the study.
RESULTS: After treatment, the total effective rate of the observation group (95.00%) was significantly higher than that of the control group (70.00%), and the difference was statistically significant (P<0.05). Compared with before treatment, the levels of NT-proBNP, cTnI, CRP, PCT, interleukin-6 and APACHE Ⅱ score in both groups decreased significantly, while LVEF and SV increased significantly, and LVEDD and LVEDV decreased significantly (P<0.05). Moreover, the improvement of the above indicators in the observation group was more significant than that in the control group, and the differences were statistically significant (P<0.05 after Bonferroni correction). No serious adverse reactions were observed in either group during the treatment period.
CONCLUSION: Shenfu Injection combined with Dapagliflozin can effectively improve the cardiac function of patients with septic HF, reduce the inflammatory response, and has good clinical efficacy and safety, which is worthy of clinical promotion and application.
METHODS: A total of 40 patients with septic HF admitted to the Intensive Care Unit (ICU) of Qingdao Jiaozhou Central Hospital from July 2019 to June 2022 were selected and randomly divided into the observation group and the control group, with 20 patients in each group. The control group was treated with Dapagliflozin tablets and basic anti-heart failure drugs, while the observation group was additionally given Shenfu Injection on the basis of the control group's treatment, with a course of 7 consecutive days. The changes of serum N-terminal B-type natriuretic peptide precursor (NT-proBNP), cardiac troponin I (cTnI), inflammatory indicators (CRP, PCT, interleukin-6), Acute Physiology and Chronic Health Evaluation Ⅱ (APACHE Ⅱ) score, and cardiac color Doppler ultrasound indicators [left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), left ventricular end-diastolic volume (LVEDV), stroke volume (SV)] were compared between the two groups before and after treatment. The clinical efficacy and safety of the two groups were evaluated. Sample size calculation was based on the primary outcome indicator of LVEF improvement. Referring to previous similar studies, the expected mean difference in LVEF improvement between the two groups was 5%, with a standard deviation of 6%. Using a two-sided test with α=0.05 and power=80%, the calculated minimum sample size per group was 18. Considering a potential dropout rate of 10%, 20 patients were included in each group to ensure the statistical power of the study.
RESULTS: After treatment, the total effective rate of the observation group (95.00%) was significantly higher than that of the control group (70.00%), and the difference was statistically significant (P<0.05). Compared with before treatment, the levels of NT-proBNP, cTnI, CRP, PCT, interleukin-6 and APACHE Ⅱ score in both groups decreased significantly, while LVEF and SV increased significantly, and LVEDD and LVEDV decreased significantly (P<0.05). Moreover, the improvement of the above indicators in the observation group was more significant than that in the control group, and the differences were statistically significant (P<0.05 after Bonferroni correction). No serious adverse reactions were observed in either group during the treatment period.
CONCLUSION: Shenfu Injection combined with Dapagliflozin can effectively improve the cardiac function of patients with septic HF, reduce the inflammatory response, and has good clinical efficacy and safety, which is worthy of clinical promotion and application.